RESUMEN
OBJECTIVE: Uterine sarcomas (USs) are characterized by poor response to systemic chemotherapy and high recurrence rates. This study evaluates whether the use of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) confers survival benefit in comparison with conventional treatment modalities in patients with recurrent US. METHODS/MATERIALS: A retrospective analysis of patients with recurrent US at a single institution for an 11-year study period was performed. All women with a pathologic diagnosis of leiomyosarcoma, adenosarcoma, endometrial stromal sarcoma, or undifferentiated US were identified. Overall and disease-free survival was estimated using Kaplan-Meier method. Comparisons between the study groups were performed with the log-rank test and Cox regression. RESULTS: A total of 26 patients were identified. Five patients received chemotherapy and/or radiotherapy without surgical intervention, 14 patients underwent surgery alone or a combination of surgery and adjuvant systemic chemotherapy, and 7 patients received cytoreductive surgery with HIPEC. There was no treatment-related mortality in any group, and only 1 patient had grade III-IV surgical complications. Median disease-free survival was 2.4 months for patients with nonsurgical treatments, 5.3 months for patients treated with conventional surgery, and 11.3 months for patients treated with HIPEC. Median overall survival was 35.9 months for patients treated with conventional surgery and 43.8 months for patients treated with HIPEC. CONCLUSIONS: Our study is the first to compare survival outcomes of HIPEC versus conventional therapies for recurrent US and is suggestive of treatment benefit. Further studies with more patients and longer follow-up to evaluate the role of HIPEC in management of this disease are warranted.
Asunto(s)
Procedimientos Quirúrgicos de Citorreducción/métodos , Hipertermia Inducida/métodos , Recurrencia Local de Neoplasia/terapia , Sarcoma/terapia , Neoplasias Uterinas/terapia , Adenosarcoma/tratamiento farmacológico , Adenosarcoma/cirugía , Adenosarcoma/terapia , Adulto , Anciano , Anciano de 80 o más Años , Quimioterapia Adyuvante , Femenino , Humanos , Persona de Mediana Edad , Recurrencia Local de Neoplasia/tratamiento farmacológico , Recurrencia Local de Neoplasia/cirugía , Estudios Retrospectivos , Sarcoma/tratamiento farmacológico , Sarcoma/cirugía , Sarcoma Estromático Endometrial/tratamiento farmacológico , Sarcoma Estromático Endometrial/cirugía , Sarcoma Estromático Endometrial/terapia , Neoplasias Uterinas/tratamiento farmacológico , Neoplasias Uterinas/cirugíaRESUMEN
OBJECTIVE: To determine the response of complex atypical hyperplasia (CAH) and well differentiated endometrioid adenocarcinoma of the uterus (WDC) to progestin therapy and whether pre-treatment estrogen and progesterone receptor status predicts outcome. METHODS: We performed a retrospective review encompassing women treated with progestin therapy for CAH or WDC at two institutions. Clinicopathologic, treatment, and recurrence data were recorded. Pre/post-treatment pathologic evaluation was performed. SAS 9.2 was used for statistical analyses. RESULTS: Forty-six patients were included. The median age was 35, and median BMI was 36.9. Thirty-seven percent were diagnosed with CAH and 63% had WDC. Megestrol acetate was the most commonly used agent (89%); 24% received multiple progestin therapies. Median treatment length was 6 months (range, 1-84); 36% of the patients underwent eventual hysterectomy, and 17.4% had carcinoma in their uterine specimens (8 primary endometrial, 1 primary ovarian). After a median follow-up of 35 months (range, 2-162), 65% experienced a complete response (CR), 28% had persistent or progressive disease, and 23% had a CR followed by recurrence. On univariate analysis, decreased post-treatment glandular cellularity (p = 0.0006), absence of post-treatment mitotic figures (p = 0.0008), and use of multiple progestin agents (p = 0.025) were associated with CR; however, only decreased glandular cellularity was significant on multivariate analysis (p = 0.007). Estrogen and progesterone receptor expression was not associated with treatment response. CONCLUSION: In women with CAH or WDC, the overall response rate to progestin therapy was 65%; pre-treatment estrogen/progesterone receptor status did not predict response to treatment.
Asunto(s)
Carcinoma Endometrioide/tratamiento farmacológico , Hiperplasia Endometrial/tratamiento farmacológico , Neoplasias Endometriales/tratamiento farmacológico , Adulto , Carcinoma Endometrioide/patología , Hiperplasia Endometrial/patología , Neoplasias Endometriales/patología , Femenino , Humanos , Persona de Mediana Edad , Progestinas , Receptores de Estrógenos/análisis , Receptores de Progesterona/análisis , Estudios RetrospectivosRESUMEN
OBJECTIVES: The aim of this study was to screen for depression and anxiety and to assess well-being among women diagnosed with gynecologic malignancies, identify factors associated with elevated depressive or anxiety symptoms, and further characterize the needs of those with elevated anxiety or depressive symptoms. METHODS/MATERIALS: Women presenting for gynecologic cancer at an academic center during the course of 10 months were offered screening for depressive and anxiety symptoms. Patients were screened with the Primary Care Evaluation of Mental Disorders' Patient Health Questionnaire-9 and the Generalized Anxiety Disorder-7. The Functional Assessment of Cancer Therapy-General assessed well-being. Demographics, psychiatric history, and components about the cancer and treatment were collected. Those who screened positive with scores of 10 or higher on the Patient Health Questionnaire-9 or the Generalized Anxiety Disorder-7 were offered a meeting with the study psychiatrist for further evaluation both with the Structured Clinical Interview for Diagnosis as well as with an interview to discuss their experiences and to assess their desired needs. RESULTS: When family and social well-being was added to the logistic regression model, higher family and social well-being was the strongest factor associated with lower amounts of anxiety (odds ratio, 0.10; P = 0.001 for a cutoff of 10; odds ratio, 0.21; P = 0.012 for a cutoff of 8). Less than 30% who screened positive met with the study psychiatrist and were not receiving optimal treatment. CONCLUSIONS: Given that low family and social well-being and elevated anxiety symptoms were so highly correlated, those with anxiety symptoms would most benefit from social interventions. However, this study also found that patients with elevated depressive or anxiety symptoms were difficult to engage with a psychiatric provider. We need partnership between psychiatry and gynecology oncology to identify those with elevated depressive and anxiety symptoms and develop better ways to provide psychosocial supports.
Asunto(s)
Trastornos de Ansiedad/prevención & control , Trastorno Depresivo/prevención & control , Neoplasias de los Genitales Femeninos/psicología , Necesidades y Demandas de Servicios de Salud , Calidad de Vida , Apoyo Social , Adulto , Trastornos de Ansiedad/epidemiología , Trastornos de Ansiedad/etiología , Terapia Combinada , Trastorno Depresivo/epidemiología , Trastorno Depresivo/etiología , Femenino , Estudios de Seguimiento , Neoplasias de los Genitales Femeninos/complicaciones , Neoplasias de los Genitales Femeninos/terapia , Humanos , Persona de Mediana Edad , Pronóstico , Pruebas Psicológicas , Encuestas y Cuestionarios , Estados Unidos/epidemiologíaRESUMEN
OBJECTIVE: To evaluate the influence of distance on access to high-volume surgical treatment for patients with uterine cancer in Maryland. METHODS: The Maryland Health Services Cost Review Commission database was retrospectively searched to identify primary uterine cancer surgical cases from 1994 to 2010. Race, type of insurance, year of surgery, community setting, and both surgeon and hospital volume were collected. Geographical coordinates of hospital and patient's zip code were used to calculate primary independent outcomes of distance traveled and distance from nearest high-volume hospital (HVH). Logistic regression was used to calculate odds ratios and confidence intervals. RESULTS: From 1994 to 2010, 8529 women underwent primary surgical management of uterine cancer in Maryland. Multivariable analysis demonstrated white race, rural residence, surgery by a high-volume surgeon and surgery from 2003 to 2010 to be associated with both travel 50 miles or more to the treating hospital and residence 50 miles or more from the nearest HVH (all P < 0.05). Patients who travel 50 miles or more to the treating hospital are more likely to have surgery at a HVH (odds ratio, 6.03; 95% confidence interval, 4.67-7.79) In contrast, patients, who reside ≥50 miles from a HVH, are less likely to have their surgery at an HVH. (odds ratio, 0.37; 95% confidence interval, 0.32-0.42). CONCLUSION: In Maryland, 50 miles or more from residence to the nearest HVH is a barrier to high-volume care. However, patients who travel 50 miles or more seem to do so to receive care by a high-volume surgeon at an HVH. In Maryland, Nonwhites are more likely to live closer to an HVH and more likely to use these services.
Asunto(s)
Accesibilidad a los Servicios de Salud/tendencias , Hospitales de Alto Volumen , Histerectomía/estadística & datos numéricos , Servicio de Cirugía en Hospital/estadística & datos numéricos , Neoplasias Uterinas/cirugía , Anciano , Estudios Transversales , Etnicidad , Femenino , Estudios de Seguimiento , Humanos , Histerectomía/tendencias , Pautas de la Práctica en Medicina , Pronóstico , Grupos Raciales , Estudios Retrospectivos , Servicio de Cirugía en Hospital/normasRESUMEN
PURPOSE OF REVIEW: To review perioperative care in gynecologic oncology with special emphasis on areas of controversy. RECENT FINDINGS: Major gynecologic surgery still represents the cornerstone of management among women diagnosed with gynecologic malignancies. The implementation of clinical guidelines can significantly impact perioperative morbidity and mortality. Preoperative evaluation and preparation allows the surgeon to identify patient risks and develop risk factor modification strategies decreasing delays in preparation and cost and improving patient safety. Preoperative areas of controversy include preoperative testing and evaluation, use of mechanical bowel preparation, prophylactic antibiotics, and use of anticoagulants, and the timing of postoperative feeding. SUMMARY: In healthy women undergoing gynecologic cancer surgery preoperative evaluation requirements will be minimal. For women with extensive comorbid conditions a more detailed evaluation will be required to decrease perioperative morbidity and mortality. Mechanical bowel preparations should not be required preoperatively. Preoperative administration of antibiotics and anticoagulants should be provided to all patients undergoing major gynecologic cancer surgery.
Asunto(s)
Neoplasias de los Genitales Femeninos/cirugía , Atención Perioperativa/métodos , Antibacterianos/uso terapéutico , Catárticos/uso terapéutico , Métodos de Alimentación , Femenino , Humanos , Atención Perioperativa/normas , Tromboembolia Venosa/prevención & controlRESUMEN
OBJECTIVE: The aim of this study was to determine if comprehensive surgical staging is a better predictor of outcome than incomplete staging for women with stage I noninvasive or minimally invasive (≤3 mm) uterine serous carcinoma (USC). METHODS: Retrospective chart review was used to identify patients undergoing hysterectomy at the Johns Hopkins Hospital from 1989 to 2010. Relevant clinical and pathologic data were extracted. Patients with noninvasive and minimally invasive (≤3-mm myometrial invasion) USC were identified. Stage was assigned based on the 2009 International Federation of Gynecology and Obstetrics endometrial cancer criteria. Survival curves were generated using the Kaplan-Meier method. RESULTS: We identified 63 patients with noninvasive or minimally invasive (≤3 mm) USC. Stages I, II, III, and IV disease were noted in 65% (41/63), 6% (4/63), 14% (9/63), and 14% (9/63) of the patients, respectively. Lower stage was associated with a significantly improved disease-specific survival (P = 0.001). Comprehensive staging, including total hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymphadenectomy, omentectomy, and peritoneal biopsies, was completed in 29% (12/41) of the patients with stage I disease. There were no disease-specific deaths in the comprehensive staging group. Compared with incomplete staging, comprehensive staging was associated with a significantly improved disease-specific survival (P = 0.039). CONCLUSIONS: Patients with stage I noninvasive and minimally invasive USC on comprehensive staging have an excellent prognosis. Adjuvant therapy may not benefit this patient population.
Asunto(s)
Cistadenocarcinoma Seroso/mortalidad , Cistadenocarcinoma Seroso/patología , Neoplasias Uterinas/mortalidad , Neoplasias Uterinas/patología , Anciano , Anciano de 80 o más Años , Baltimore/epidemiología , Cistadenocarcinoma Seroso/cirugía , Supervivencia sin Enfermedad , Femenino , Humanos , Persona de Mediana Edad , Invasividad Neoplásica , Estadificación de Neoplasias , Sistema de Registros , Estudios Retrospectivos , Análisis de Supervivencia , Neoplasias Uterinas/cirugíaRESUMEN
BACKGROUND: The management of patients with liver metastasis from a gynecologic carcinoma remains controversial, as there is currently little data available. We sought to determine the safety and efficacy of liver-directed surgery for hepatic metastasis from gynecologic primaries. METHODS: Between 1990 and 2010, 87 patients with biopsy-proven liver metastasis from a gynecologic carcinoma were identified from an institutional hepatobiliary database. Fifty-two (60%) patients who underwent hepatic surgery for their liver disease and 35 (40%) patients who underwent biopsy only were matched for age, primary tumor characteristics, and hepatic tumor burden. Clinicopathologic, operative, and outcome data were collected and analyzed. RESULTS: Of the 87 patients, 30 (34%) presented with synchronous metastasis. The majority of patients had multiple hepatic tumors (63%), with a median size of the largest lesion being 2.5 cm. Of those patients who underwent liver surgery (n=52), most underwent a minor hepatic resection (n=44; 85%), while 29 (56%) patients underwent concurrent lymphadenectomy and 45 (87%) patients underwent simultaneous peritoneal debulking. Postoperative morbidity and mortality were 37% and 0%, respectively. Median survival from time of diagnosis was 53 months for patients who underwent liver-directed surgery compared with 21 months for patients who underwent biopsy alone (n=35) (p=0.01). Among those patients who underwent liver-directed surgery, 5-year survival following hepatic resection was 41%. CONCLUSIONS: Hepatic surgery for liver metastasis from gynecologic cancer can be performed safely. Liver surgery may be associated with prolonged survival in a subset of patients with hepatic metastasis from gynecologic primaries and therefore should be considered in carefully selected patients.
Asunto(s)
Carcinoma/secundario , Neoplasias de los Genitales Femeninos/patología , Hepatectomía/métodos , Neoplasias Hepáticas/secundario , Neoplasias Hepáticas/cirugía , Adulto , Anciano , Anciano de 80 o más Años , Biopsia con Aguja , Carcinoma/mortalidad , Carcinoma/cirugía , Estudios de Cohortes , Femenino , Neoplasias de los Genitales Femeninos/cirugía , Hepatectomía/mortalidad , Humanos , Inmunohistoquímica , Estimación de Kaplan-Meier , Neoplasias Hepáticas/mortalidad , Persona de Mediana Edad , Estadificación de Neoplasias , Pronóstico , Estudios Retrospectivos , Medición de Riesgo , Estadísticas no Paramétricas , Análisis de Supervivencia , Resultado del TratamientoRESUMEN
OBJECTIVE: To compare the survival impact of diagnosing recurrent disease by routine surveillance testing versus clinical symptomatology in patients with recurrent epithelial ovarian cancer (EOC) who have achieved a complete response following primary therapy. METHODS: We identified all patients who underwent primary surgery for EOC at two institutions between 1/1997 and 12/2004 and were diagnosed with recurrent disease following a complete clinical response to primary chemotherapy. Survival and post-recurrence management were compared between asymptomatic patients in which recurrent disease was diagnosed at a scheduled visit by routine surveillance testing and symptomatic patients in which recurrent disease was diagnosed based on clinical symptomatology at an unscheduled office visit or hospitalization. RESULTS: Of the 121 patients that met inclusion criteria, 22 (18.2%) were diagnosed with a symptomatic recurrence. Median primary PFS was similar for asymptomatic and symptomatic patients (24.8 versus 22.6 months, P = 0.36); however, post-recurrence survival was significantly greater in asymptomatic patients (45.0 versus 29.4 months, P = 0.006). Secondary cytoreductive surgery (SCRS) was attempted equally in both groups (41% versus 32%, P = NS); however, optimal residual disease (Asunto(s)
Recurrencia Local de Neoplasia/diagnóstico
, Neoplasias Ováricas/diagnóstico
, Adulto
, Anciano
, Anciano de 80 o más Años
, Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico
, Hidrocarburos Aromáticos con Puentes/administración & dosificación
, Estudios de Casos y Controles
, Quimioterapia Adyuvante
, Supervivencia sin Enfermedad
, Femenino
, Humanos
, Histerectomía
, Persona de Mediana Edad
, Recurrencia Local de Neoplasia/patología
, Estadificación de Neoplasias
, Compuestos Organoplatinos/administración & dosificación
, Neoplasias Ováricas/tratamiento farmacológico
, Neoplasias Ováricas/patología
, Neoplasias Ováricas/cirugía
, Ovariectomía
, Estudios Retrospectivos
, Taxoides/administración & dosificación
RESUMEN
BACKGROUND: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) after neoadjuvant chemotherapy (NACT) showed promise as initial treatment for stage IIIC (SIII) epithelial ovarian cancer (EOC); however, stage IV (SIV) outcomes are rarely reported. We assessed our experience and outcomes treating newly diagnosed SIV EOC with NACT plus CRS/HIPEC compared to SIII patients. METHODS: Advanced EOC from 2015-2018 managed with NACT (carboplatin/paclitaxel) due to unresectable disease or poor performance status followed by interval CRS/HIPEC were reviewed. Perioperative factors were assessed. Overall survival (OS) and progression-free survival (PFS) were analyzed by stage. RESULTS: Twenty-seven FIGO stage IIIC (n = 12) and IV (n = 15) patients were reviewed. Median NACT cycles were 3 and 4, respectively. Post-NACT omental caking, ascites, and pleural effusions decreased/resolved in 91%, 91%, and 100% of SIII and 85%, 92%, and 71% of SIV. SIII/SIV median PCI was 21 and 20 obtaining 92% and 100% complete cytoreduction (≤0.25 cm), respectively. Median organ resections were 6 and 7, respectively. Grade III/IV surgical complications were 0% SIII and 23% SIV, without hospital mortality. Median time to adjuvant chemotherapy was 53 and 74 days, respectively (p=0.007). SIII OS at 1 and 2 years was 100% and 83% and 87% and 76% in SIV (p=0.269). SIII 1-year PFS was 54%; median PFS: 12 months. SIV 1- and 2- year PFS was 47% and 23%; median PFS: 12 months (p=0.944). CONCLUSION: Outcomes in select initially diagnosed and unresectable SIV EOC are similar to SIII after NACT plus CRS/HIPEC. SIV EOC may benefit from CRS/HIPEC, and further studies should explore this treatment approach.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma Epitelial de Ovario/terapia , Neoplasias Ováricas/patología , Neoplasias Ováricas/terapia , Neoplasias Peritoneales/terapia , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Carboplatino/administración & dosificación , Carcinoma Epitelial de Ovario/secundario , Quimioterapia Adyuvante , Procedimientos Quirúrgicos de Citorreducción/efectos adversos , Femenino , Humanos , Quimioterapia Intraperitoneal Hipertérmica , Persona de Mediana Edad , Terapia Neoadyuvante , Estadificación de Neoplasias , Paclitaxel/administración & dosificación , Neoplasias Peritoneales/secundario , Complicaciones Posoperatorias/etiología , Supervivencia sin Progresión , Tasa de SupervivenciaRESUMEN
BACKGROUND: Positive volume-outcome relationships exist for cancers treated with technically complex surgery, including ovarian cancer. However, contemporary patterns of primary surgical care for ovarian cancer according to hospital and surgeon case volume remain poorly defined. METHODS: The Maryland Health Service Cost Review Commission database was accessed for annual hospital and surgeon primary ovarian cancer surgical case volume for 2001-2008 and evaluated for statistically significant trends in access to high-volume surgical care compared with the earlier period for 1990-2000. chi(2) and logistic regression analyses were used to evaluate for significant trends in case volume distribution over time as well as factors associated with access to high-volume care. RESULTS: Overall, 2,475 primary ovarian cancer operations were performed by 472 surgeons at 43 hospitals. There was a statistically significant increase in the proportion of cases performed at high-volume centers from 22.8% in 1990-2000 to 61.1% in 2001-2008 (odds ratio = 5.30, 95% confidence interval = 4.68-6.00, P < .0001), while low-volume hospital case distribution decreased from 49.6 to 31.3%. Access to high-volume surgeons increased from 34.5% in 1990-2000 to 64.5% in 2001-2008 (odds ratio = 3.44, 95% confidence interval = 3.06-3.87, P < .0001), while the proportion of cases performed by low-volume surgeons decreased from 56.3 to 28.9%. After controlling for other variables, high-volume surgeons were significantly more likely to perform ovarian cancer surgery that included hysterectomy and staging/cytoreductive surgical procedures. CONCLUSIONS: The proportions of ovarian cancer patients undergoing primary surgery at high volume centers and by high-volume surgeons increased statistically significantly from 1990-2000 to 2001-2008. Further investigation is necessary to determine factors contributing to this favorable trend.
Asunto(s)
Procedimientos Quirúrgicos Ginecológicos/normas , Histerectomía/estadística & datos numéricos , Neoplasias Ováricas/cirugía , Ovariectomía/estadística & datos numéricos , Servicio de Cirugía en Hospital/estadística & datos numéricos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Estudios Transversales , Femenino , Humanos , Histerectomía/tendencias , Persona de Mediana Edad , Neoplasias Ováricas/economía , Neoplasias Ováricas/mortalidad , Ovariectomía/tendencias , Pautas de la Práctica en Medicina , Pronóstico , Tasa de Supervivencia , Resultado del Tratamiento , Adulto JovenRESUMEN
OBJECTIVE: To evaluate the impact of surgeon and hospital case volume, and other related variables, on short-term outcomes after surgery for ovarian cancer. METHODS: The Maryland Health Service Cost Review Commission database was accessed for ovarian cancer surgical cases including both oophorectomy and any staging/cytoreductive surgical procedure from 2001 to 2008. Multivariate logistic regression analyses and multiple linear regression models were used to evaluate for significant associations between surgeon and hospital case volume, as well as other independent variables, and the risk of in-hospital death, extent of surgery, length of hospital stay, and hospital-related cost of care. RESULTS: Overall, 1894 primary ovarian cancer operations were performed by 352 surgeons at 43 hospitals. After controlling for the effects of all variables, the only independently significant factors associated with the risk of in-hospital death were surgery by a high-volume surgeon and an APR-DRG mortality risk score of 4. Ovarian cancer surgery performed by a high-volume surgeon was associated with a 69% reduction in the risk of in-hospital death. Surgery at a high-volume hospital was an independent positive predictor of a cytoreductive procedure. A statistically significant negative correlation was observed between surgery at a high-volume hospital and both length of hospital stay and hospital-related cost. CONCLUSIONS: After controlling for other factors, ovarian cancer surgery performed by a high-volume surgeon is associated with a 69% reduction in the risk of in-hospital death, while high-volume hospital care is associated with increased likelihood of cytoreduction, shorter length of stay, and lower hospital-related cost of care.
Asunto(s)
Procedimientos Quirúrgicos Ginecológicos/métodos , Procedimientos Quirúrgicos Ginecológicos/normas , Neoplasias Ováricas/cirugía , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Procedimientos Quirúrgicos Ginecológicos/efectos adversos , Mortalidad Hospitalaria , Humanos , Modelos Logísticos , Persona de Mediana Edad , Ovariectomía/efectos adversos , Ovariectomía/métodos , Ovariectomía/normas , Adulto JovenRESUMEN
OBJECTIVE: To characterize primary surgical care for women with ovarian cancer aged =50 years versus > 50 years. METHODS: A statewide hospital discharge database was used to identify women undergoing primary surgery for ovarian cancer from 1990 to 2000. Logistic regression models were used to evaluate differences in demographic characteristics and short-term outcomes comparing women =50 years versus >50 years. RESULTS: Women =50 years comprised 30.2% (n=731) of 2417 identified cases. The 30-day mortality rate was 54% lower among women =50 years (1.2% vs. 2.6%, P=0.0100). Women =50 years were less likely to be managed by high-volume surgeons versus women >50 years (47.1% vs. 59.5%, P<0.0001). Younger women managed by high-volume surgeons had longer lengths of stay (5.7 days vs. 7.7 days, P<0.0001), longer ICU stays (0.2 days vs. 0.5 days, P=0.0020), more billed procedures (4.2 vs. 5.5, P<0.0001), higher adjusted cost of hospital-related care ($46,590 vs. $97,538, P<0.0001) and more comorbidities (1.0 vs. 1.6, P<0.0001) than those treated by lower-volume surgeons. Women =50 years were as likely to be managed at high volume centers as low volume centers (57.7% vs. 61.3% P=0.0968). A similar trend in outcomes was observed in younger women treated at high-versus low-volume hospitals as high-versus low-volume surgeons. CONCLUSION: Primary surgical care for ovarian cancer in women =50 years is often performed by low-volume providers at low-volume centers. In light of positive volume-outcome data for malignancies treated with complex operative procedures, further efforts to characterize the surgical care of young women with ovarian cancer are warranted.
Asunto(s)
Procedimientos Quirúrgicos Ginecológicos/normas , Neoplasias Ováricas/cirugía , Factores de Edad , Femenino , Procedimientos Quirúrgicos Ginecológicos/economía , Procedimientos Quirúrgicos Ginecológicos/métodos , Procedimientos Quirúrgicos Ginecológicos/estadística & datos numéricos , Costos de la Atención en Salud , Humanos , Tiempo de Internación , Modelos Logísticos , Maryland/epidemiología , Persona de Mediana Edad , Neoplasias Ováricas/economía , Neoplasias Ováricas/epidemiologíaRESUMEN
OBJECTIVE: To evaluate the feasibility and impact on cost to the U.S. healthcare system of implementing a clinical pathway for Pap test utilization in screening and surveillance of gynecologic cancers in a university-based gynecologic oncology practice. METHODS: Baseline data were collected for Pap test utilization between 1/1/04 and 6/30/05 and prospectively compared to Pap test utilization following the implementation of a clinical pathway (7/1/05 to 5/30/06). The clinical pathway: 1) employed ACOG guidelines for asymptomatic screening of non-cancer patients, 2) allowed testing at 4 months intervals for cervical/vaginal cancer surveillance, 3) limited testing for endometrial cancer surveillance to 2 tests/60 months, and 4) eliminated testing as part of ovarian cancer surveillance. Relevant costs were calculated using Medicare charge-to-cost ratios and adjusted to 2006 USD. For statistical analysis, differences in Pap test utilization and cost were evaluated using student's t-test. RESULTS: During the baseline period, 1725 Pap tests were collected from 5605 ambulatory encounters, for a Pap test rate of 30.8% and an annualized cost of $93,759. After implementation of the clinical pathway, 4209 ambulatory encounters yielded an annual Pap test rate of 11% and an annual cost of $35,728 (p<0.0001), a savings of $58,031. In addition, clinical pathway implementation also registered an opportunity cost savings of 180.3 nursing personnel work hours ($4,162). CONCLUSIONS: Reduction in the unnecessary use of Pap testing for asymptomatic screening and surveillance for gynecologic cancers through a straightforward clinical pathway is feasible and offers an opportunity for significant cost savings in gynecologic oncology healthcare expenditure.
Asunto(s)
Vías Clínicas/economía , Frotis Vaginal/economía , Frotis Vaginal/estadística & datos numéricos , Estudios de Factibilidad , Femenino , Neoplasias de los Genitales Femeninos/diagnóstico , Neoplasias de los Genitales Femeninos/economía , Neoplasias de los Genitales Femeninos/patología , Ginecología/economía , Ginecología/métodos , Ginecología/normas , Costos de la Atención en Salud , Humanos , Tamizaje Masivo/economía , Tamizaje Masivo/métodos , Tamizaje Masivo/normas , Tamizaje Masivo/estadística & datos numéricos , Oncología Médica/economía , Oncología Médica/métodos , Oncología Médica/normas , Frotis Vaginal/métodos , Frotis Vaginal/normasRESUMEN
OBJECTIVES: To evaluate the safety, feasibility, and economic impact of a clinical pathway, including rapid diet advancement, for patients undergoing rectosigmoid colectomy as part of cytoreductive surgery for advanced ovarian and primary peritoneal cancers. METHODS: Between 8/1/98 and 6/30/06, 64 consecutive patients met study inclusion criteria. Using case-control methodology, post-operative management was dictated by a prescribed clinical pathway in 19 patients (Group A) and directed by individual surgeon preference in 45 patients (Group B). Critical elements of the clinical pathway included: rapid diet advancement, early discontinuance of nasogastric suction, criteria-based utilization of parenteral nutrition, selective laboratory testing, and deferring initiation of chemotherapy until after discharge. RESULTS: Stage IIIC/IV disease was present in 94% of all patients. The median time to flatus was 6 days for both groups (p=0.95); however, the median time to tolerance of diet was 3 days for Group A and 6 days for Group B (p=0.013). Compared to Group B, patients in Group A had a significantly shorter median length of hospital stay (7 days vs 10 days, p=0.014) and lower median 30-day post-operative hospital cost ($19,700 vs $25,110, p=0.028), with no significant difference in 30-day readmission rate (21% vs 33%, p=0.379). Clinical pathway-directed management was associated with a median reduction in hospital cost of $5410 per patient. CONCLUSIONS: A critical pathway incorporating rapid diet advancement for patients undergoing primary cytoreductive surgery with rectosigmoid colectomy for ovarian and primary peritoneal cancers is feasible, safe, and associated with a significant reduction in length of hospital stay and hospital-related costs.
Asunto(s)
Colectomía/métodos , Neoplasias Ováricas/cirugía , Neoplasias Peritoneales/cirugía , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Colectomía/economía , Dieta , Femenino , Humanos , Intubación Gastrointestinal , Persona de Mediana Edad , Estadificación de Neoplasias , Neoplasias Ováricas/economía , Neoplasias Ováricas/patología , Neoplasias Peritoneales/economía , Neoplasias Peritoneales/patología , Cuidados Posoperatorios/métodosRESUMEN
OBJECTIVES: To characterize the primary surgical care and short-term outcomes for uterine cancer in women age > or = 80 years compared to younger women. METHODS: A statewide hospital discharge database was used to identify women that underwent primary surgery for uterine cancer from 1994 to 2005. Logistic regression models were used to evaluate for significant differences in demographic characteristics and short-term outcomes comparing women aged > or = 80 years with those aged < 80 years. RESULTS: A total of 6181 women were identified, women aged > or = 80 years comprised 10.6% (n=656) of cases. Elderly women were 1.3 times more likely to be managed by high volume surgeons (41% vs. 35%, p=0.00). The 30-day mortality rate was 4.3 fold higher for the elderly group (4.27% vs. 1.03%, p=0.00). Among the elderly group, there was a 62% reduction in the risk of 30-day mortality when they were managed at high volume hospitals (95% CI: 0.18-0.80, p=0.01), and a 44% reduction in the risk of 30-day mortality when management was performed by high volume surgeons (95% CI: 0.21-1.48, p=0.22). The cost of care among elderly women managed at high volume centers ($10,425 vs. $9454, p=0.02) and by high volume surgeons ($11,260 vs. $9400, p<0.00) was higher when compared to the low volume groups. CONCLUSIONS: Primary surgical care of elderly women with uterine cancer by high volume providers is associated with better short-term outcomes but increases healthcare expenditure compared to low volume providers. Increased efforts to concentrate the operative care of this patient population in experienced, high volume centers are warranted.
Asunto(s)
Neoplasias Uterinas/cirugía , Adolescente , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Estudios Transversales , Femenino , Procedimientos Quirúrgicos Ginecológicos/métodos , Procedimientos Quirúrgicos Ginecológicos/estadística & datos numéricos , Humanos , Maryland/epidemiología , Persona de Mediana Edad , Resultado del Tratamiento , Neoplasias Uterinas/epidemiología , Neoplasias Uterinas/mortalidadRESUMEN
OBJECTIVE: To identify perioperative variables associated with length of stay in the surgical intensive care unit (SICU), and overall cost of hospitalization in order to optimize resource utilization among patients undergoing surgery for ovarian cancer. METHODS: A retrospective analysis of patients admitted to the SICU immediately after surgery for ovarian cancer between 1/1/94 and 6/30/04 was performed. Patients admitted to the SICU were categorized in two groups. Those admitted for < 48 h were compared patients requiring a SICU stay > or = 48 h. Perioperative variables were compared across the two groups by univariate and multivariate logistic regression analysis. RESULTS: A total of 95 patients were admitted to the SICU immediately after surgical management for ovarian cancer, with 57% requiring a stay > or = 48 h. Patient age = 63 years was associated with an increase risk of admission to the SICU for > or = 48 h (OR: 5.9, 95% CI: 1.72-20.50, p=0.005). Patients with administration of > or = 5 l of crystalloid solution during surgery were 8 times more likely to have prolonged admission to the SICU (95% CI: 2.34-27.57, p=0.001). Furthermore, a preoperative serum albumin level > or = 3.5 g/dl was associated with a reduction in the risk of prolonged admission to the SICU (OR: 0.23, 95% CI: 0.07-0.77, p=0.02). The average cost of hospitalization per patient was $33,086. Cost of hospital care was strongly associated with SICU length of stay (p=0.005). CONCLUSION: Extensive fluid resuscitation during surgery, poor nutritional status, and > or = 63 years are associated with a prolonged postoperative SICU stay. These data may facilitate a reduction in unnecessary ICU admissions for patients without these risk factors and thereby optimize resource utilization following surgery for ovarian cancer.
Asunto(s)
Cuidados Críticos/estadística & datos numéricos , Neoplasias Ováricas/cirugía , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Cuidados Críticos/economía , Cuidados Críticos/métodos , Femenino , Costos de Hospital , Humanos , Persona de Mediana Edad , Neoplasias Ováricas/economía , Cuidados Posoperatorios/economía , Cuidados Posoperatorios/métodos , Cuidados Posoperatorios/estadística & datos numéricos , Estudios RetrospectivosRESUMEN
OBJECTIVE: Uterine sarcoma (US) is a rare tumor representing 1% of female genital tract malignancies. Peritoneal sarcomatosis (PS) after US, diminishes median overall survival (OS) and progression-free survival (PFS) with cytoreductive surgery (CRS) alone, with or without systemic chemotherapy is <1 year and 6 months, respectively. A multi-institutional review of PS from US was conducted to evaluate CRS and hyperthermic intraperitoneal chemotherapy (HIPEC) and effects on survival outcomes. METHODS: A retrospective review of 36 patients from 7 specialized international centers was performed. Selection criteria included PS of uterine origin with CRS/HIPEC treatment. Clinical data were analyzed. OS and PFS were estimated with Kaplan-Meier method. RESULTS: Thirty-six patients underwent a total 38 HIPEC procedures performed from 2005 to 2014; 35 previous treatment and 1 primary treatment. Twenty-nine (81%) LMS patients, 3 (8%) endometrial stromal sarcoma (ESS), 3 (8%) adeneosarcoma (AS), and 1 (3%) categorized as other. Median PCI was 16 (range: 2-39), 10 patients had PCI ≥20. Thirty-four patients (94%) had complete cytoreduction (CC 0-1), 19 patients recurred. CRS/HIPEC OS at 1, 3, and 5-years was 75%, 53%, and 32% respectively, with median OS of 37 months (CI 95%: 20-54). PFS in 32 patients with CC at 1, 3, and 5-years was 67%, 32% and 32%, respectively with median PFS of 18.9 months (CI 95%: 6.7-31). CONCLUSIONS: CRS/HIPEC is a promising treatment modality for patients with PS. Histological subtype may influence survival. A global prospective registry of patients to further assess the efficacy of CRS/HIPEC is needed.
Asunto(s)
Quimioterapia del Cáncer por Perfusión Regional , Procedimientos Quirúrgicos de Citorreducción , Hipertermia Inducida , Neoplasias Peritoneales/secundario , Neoplasias Peritoneales/terapia , Sarcoma/secundario , Sarcoma/terapia , Neoplasias Uterinas/patología , Adulto , Anciano , Terapia Combinada , Femenino , Humanos , Persona de Mediana Edad , Tasa de Supervivencia , Resultado del TratamientoRESUMEN
Introduction. Ovarian cancer is the deadliest gynecologic cancer in the United States. There is limited data on presentation and outcomes among Hispanic women with ovarian cancer. Objective. To investigate how ovarian cancer presents among Hispanic women in the USA and to analyze differences in presentation, staging, and survival between Hispanic and non-Hispanic women with ovarian cancer. Methods. Data from January 1, 2000 to December 31, 2004 were extracted from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) database. Results. The study sample comprised 1215 Hispanics (10%), 10 652 non-Hispanic whites (83%), and 905 non-Hispanic blacks (7%). Hispanic women were diagnosed with ovarian cancer at a younger age and earlier stage when compared to non-Hispanic whites, non-Hispanic blacks; P < 0.001. Similar proportion of Hispanics (33%), non-Hispanic whites (32%), and non-Hispanic blacks (24%) underwent lymphadenectomy; P < 0.001. Hispanics with epithelial ovarian cancer histology had longer five-year survival of 30.6 months compared to non-Hispanic whites (22.8 months) and non-Hispanic blacks (23.3 months); P = 0.001. Conclusion. Hispanic women with ovarian cancer have a statistically significantly longer median survival compared to whites and blacks. This survival difference was most apparent in patients with epithelial cancers and patients with stage IV disease.